We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+1.57%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.92B
AUM Growth
+$129M
Cap. Flow
+$265M
Cap. Flow %
13.75%
Top 10 Hldgs %
49.82%
Holding
94
New
22
Increased
32
Reduced
16
Closed
13

Top Buys

Rank Stock Value
1
SYK icon
Stryker
SYK
+$65.4M
2
EW icon
Edwards Lifesciences
EW
+$64.1M
3
RAPP
Rapport Therapeutics
RAPP
+$45.2M
4
ALGN icon
Align Technology
ALGN
+$34.3M
5
AXSM icon
Axsome Therapeutics
AXSM
+$23M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$85.9M
2
INCY icon
Incyte
INCY
+$75.6M
3
ARGX icon
argenx
ARGX
+$58.8M
4
INBX
Inhibrx, Inc. Common Stock
INBX
+$45.5M
5
PODD icon
Insulet
PODD
+$28.7M

Sector Composition

Rank Sector Weight
1 Healthcare 82.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QQQ icon
1
PUT
Invesco QQQ Trust
QQQ
$455B
$192M 9.96%
+400,000
New +$180M
NTRA icon
2
Natera
NTRA
$37.5B
$168M 8.72%
1,550,280
– –
VERA icon
3
Vera Therapeutics
VERA
$2.54B
$101M 5.25%
2,793,987
– –
ASND icon
4
Ascendis Pharma A/S
ASND
$16.7B
$100M 5.2%
734,284
-19,748
-3% -$2.69M
NVO
5
Novo Nordisk
NVO
$216B
$92.7M 4.82%
649,541
+37,657
+6% +$4.99M
EW icon
6
Edwards Lifesciences
EW
$47.6B
$66.9M 3.48%
+724,225
New +$64.1M
SYK icon
7
Stryker
SYK
$127B
$65.7M 3.41%
+193,084
New +$65.4M
AZN icon
8
AstraZeneca
AZN
$263B
$62.5M 3.25%
400,709
+102,352
+34% +$15.4M
DYN icon
9
Dyne Therapeutics
DYN
$4.04B
$57.4M 2.98%
1,625,703
-310,947
-16% -$9.04M
ALGN icon
10
Align Technology
ALGN
$12B
$52.8M 2.74%
218,524
+123,046
+129% +$34.3M
EW icon
11
PUT
Edwards Lifesciences
EW
$47.6B
$46.2M 2.4%
+500,000
New +$44.3M
RAPP
12
Rapport Therapeutics
RAPP
$1.95B
$45.4M 2.36%
+1,951,562
New +$45.2M
SNDX icon
13
Syndax Pharmaceuticals
SNDX
$1.84B
$44.2M 2.3%
2,153,669
+545,129
+34% +$11.4M
ELAN icon
14
Elanco Animal Health
ELAN
$12.4B
$41.3M 2.15%
2,864,250
+308,703
+12% +$4.93M
ABT icon
15
CALL
Abbott
ABT
$180B
$40.5M 2.11%
+390,200
New +$41.4M
IDYA icon
16
IDEAYA Biosciences
IDYA
$3.41B
$40.4M 2.1%
1,151,528
+369,932
+47% +$14.6M
ISRG icon
17
Intuitive Surgical
ISRG
$121B
$38.8M 2.02%
87,217
-53,663
-38% -$21.4M
ALNY icon
18
Alnylam Pharmaceuticals
ALNY
$36.3B
$35.9M 1.87%
147,929
+44,893
+44% +$7.09M
TGTX icon
19
TG Therapeutics
TGTX
$8.58B
$33.1M 1.72%
1,861,277
-123,685
-6% -$1.97M
AVBP icon
20
ArriVent BioPharma
AVBP
$1.48B
$31.5M 1.64%
1,696,752
– –
IDXX icon
21
Idexx Laboratories
IDXX
$42.9B
$31.1M 1.62%
63,862
-11,362
-15% -$5.7M
SRPT icon
22
Sarepta Therapeutics
SRPT
$1.66B
$30.9M 1.61%
195,852
-31,636
-14% -$4.06M
YMAB
23
DELISTED
Y-mAbs Therapeutics
YMAB
$26.5M 1.38%
2,194,278
– –
AXSM icon
24
Axsome Therapeutics
AXSM
$12.4B
$25M 1.3%
+310,198
New +$23M
COGT icon
25
Cogent Biosciences
COGT
$6.79B
$23.4M 1.22%
2,773,286
+372,515
+16% +$2.83M
1
2 3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q2 2024 Portfolio in Review

As of Q2 2024, Sofinnova Investments held 94 positions worth $1.92B, up 7.2% from $1.8B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Sofinnova Investments deployed $265M of net new capital in Q2 2024, opening 22 new positions and adding to 32 existing holdings. Its largest new stake was Stryker: 193,084 shares worth $65.7M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 94% a quarter earlier.

On the sell side, the largest reduction was Insulet, an estimated $28.7M trimmed.

  • Sofinnova Investments's largest Q2 2024 buy was Stryker: 193,084 shares worth $65.7M.
  • Sofinnova Investments added most to Align Technology in Q2 2024, an estimated $34.3M increase.
  • Sofinnova Investments's biggest Q2 2024 reduction was Insulet, cutting an estimated $28.7M.
  • Sofinnova Investments fully exited Merck in Q2 2024, selling an estimated $85.9M.
  • Sofinnova Investments's ten largest holdings make up 50% of its $1.92B portfolio in Q2 2024.
  • Sofinnova Investments opened 22 new positions and closed 13 in Q2 2024.
  • Sofinnova Investments's portfolio value rose 7.2% quarter-over-quarter to $1.92B.

Based on Sofinnova Investments's 13F filing for Q2 2024, filed 9 Aug 2024.